NASDAQ
BRKR
Last Price
US $59.83
KEY FIGURES
MKT CAP
$9.1B
EPS
TTM
$-0.08
PEG
TTM
N/M
P/E
TTM
N/M
P/S
TTM
2.63x
YIELD
0.33%
GROWTH
Revenue Y/Y
Profit margin
Current Ratio
Capital Returns
-0.51%
Return on equity
ROIC: -2.92%
Valuation History
-251.3X
Price to Earnings
EV/EBITDA: 35.3X
Cash flow
Profit margin
11.57%
(FY vs FY)
EBITDA Y/Y
-1.15%
(FY vs FY)
Cash flow Y/Y
-43.19%
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $59.83
—
Default assumptions
EBITDA Multiple
Fair Value
Market $59.83
-97.04%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Bruker Corporation cash flow to debt ratio of 6.56% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
Bruker Corporation's free cash flow has decreased -89.78% from $136.00M last year to $13.90M, signaling decreasing performance
Financial risk - Healthy debt to equity ratio.
Bruker Corporation's debt to equity ratio is 0.68, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy
Financial stability - Healthy debt to equity ratio development.
Bruker Corporation's debt has decreased relative to shareholder equity from 1.26 last year to 0.68 today, signaling strengthened financials
Financial risk - Net debt/EBITDA.
Bruker Corporation has a net debt to EBITDA ratio of 5.76x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk
Financial stability - ICR.
Bruker Corporation's interest coverage ratio of 3.43 indicates that earnings with margin can cover interest payments on company debt
Financial risk - Profit margin growth.
Bruker Corporation's profit margin has decreased (-109.98%) in the last year from 3.36% to -0.34%, signaling decreasing performance
Financial stability - Short term assets vs short term liabilities.
Bruker Corporation's short-term assets of $2.21G exceed its short-term liabilities of $1.28G
Decreasing performance - ROA.
Bruker Corporation's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Bruker Corporation's return on equity of -0.51%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Bruker Corporation's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Increasing performance - Earnings stability.
Bruker Corporation had positive net income in 4.00 out of 5 years, indicating stable and consistent earnings
Increasing performance - Free cash flow.
Bruker Corporation has positive free cash flow, indicating the company generates cash after capital expenditures
Decreasing performance - FCF yield.
Bruker Corporation has a free cash flow yield of 0.15%, which is below the 2.00% threshold, indicating limited cash return relative to market value
Decreasing performance - Healthy earnings growth.
Bruker Corporation's yearly earnings has decreased -107.60% since last year from $113.10M to $-8.60M, signaling decreasing performance
Increasing performance - Healthy revenue growth.
Bruker Corporation's yearly revenue has increased 2.08% since last year from $3.37G to $3.44G, signaling increasing performance
Decreasing performance - ROIC.
ROIC -2.92% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Increasing performance - 3-year revenue CAGR.
Bruker Corporation's 3-year revenue CAGR of 10.74% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
Bruker Corporation had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance
Increasing performance - ROE consistency.
Bruker Corporation had positive ROE in 4.00 out of 5 years, indicating consistent and reliable returns on equity
Overvalued - DCF valuation.
Bruker Corporation has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Bruker Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Bruker Corporation is overvalued relative to its fair value price of 1.77 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Bruker Corporation has an EV/EBITDA ratio of 35.86x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings
Overvalued - PEG ratio value.
Bruker Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
Bruker Corporation has a price-to-book ratio of 3.64x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
Bruker Corporation has a price-to-sales ratio of 2.63x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue